Opens in a new tab

EOFLOW v Insulet (CoA, 9 October 2024)

Date9 October 2024
CourtCoA
DivisionLuxembourg (LU)
Type of actionGeneric Order
Registry referenceORD_55415/2024
PartiesEOFLOW Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 9 October 2024 (UPC_CoA_584/2024), the Court of Appeal refused EOFlow’s request to expedite its appeal against the order of 24 September 2024 of the Milan Central Division, which had declined to join Insulet’s application for provisional measures against EOFlow (EP 4 201 327) with its parallel application against Menarini before the Milan Local Division. With oral hearings listed for 15 and 16 October 2024, a ruling beforehand would have meant cutting Insulet’s time to respond substantially. The order shows that a party which is slow to come to the Court bears the cost of its own delay.

Question

Should the Court of Appeal expedite the appeal and shorten the respondent’s 15-day period for replying to the statement of grounds of appeal?

Decision

The request was admissible (paragraph 11). Rule 9.3(b) allows a time period to be shortened on a reasoned request, but EOFlow’s arguments did not outweigh Insulet’s interests and the requirements of due process (paragraphs 13 to 15). EOFlow had not explained why it waited for the decision on Menarini’s intervention before appealing. Its ten-day delay would require Insulet’s time to be cut substantially, although EOFlow itself had taken longer than the time Insulet would be left with (paragraphs 16 and 17). Given the outcome, the Court ruled without hearing Insulet (paragraph 12).

Key points for practice

Provisions applied

Rules of Procedure
Rules 9.3(b), 224.2(b), 225(e), 235, 333 and 340.1
Case law cited
No UPC decision is cited.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic Order
Outcome (Dhenne Avocats summary)
La cour d’appel refuse d’accélérer l’appel d’EOFlow contre le refus de jonction et d’abréger le délai de réponse d’Insulet, faute pour EOFlow d’avoir justifié son propre retard.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.